FRAXA-DVI research team in the lab conducting preclinical Fragile X drug validation studies

FRAXA Drug Validation Initiative (FRAXA-DVI)

The FRAXA Drug Validation Initiative (FRAXA-DVI) provides streamlined, cost-effective preclinical testing to evaluate investigational and repurposed compounds for Fragile X syndrome.

Read More »

Finding Fragile X Biomarkers – From Transcriptomics to Behavior in Patients

FRAXA funded a study using blood-based transcriptomics to find reliable Fragile X biomarkers. This unique approach links molecular data to behavior for future trials.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (38)